Bristol Myers Squibb (BMY) Change in Accured Expenses (2021 - 2026)

Bristol Myers Squibb (BMY) has 6 years of Change in Accured Expenses data on file, last reported at -$3.5 billion in Q1 2026.

• Change in Accured Expenses for Q1 2026 came in at -$3.5 billion, down 457.42% year-over-year; the trailing twelve-month figure through Mar 2026 was -$3.3 billion (down 317.41% YoY), and the FY2025 annual result was -$441.0 million, down 129.72% from the prior year.
• Change in Accured Expenses declined to -$3.5 billion in Q1 2026 per BMY's latest filing, from -$2.4 billion in the prior quarter.
• Over five years, Change in Accured Expenses peaked at $1.8 billion in Q3 2024 and troughed at -$3.5 billion in Q1 2026.
• A 5-year average of -$65.9 million and a median of -$211.0 million in 2023 frame the typical range for Change in Accured Expenses.
• On a YoY basis, Change in Accured Expenses climbed as much as 141.86% in 2022 and fell as far as 676.92% in 2022.
• A 5-year view of Change in Accured Expenses shows it stood at -$303.0 million in 2022, then soared by 30.36% to -$211.0 million in 2023, then sank by 91.94% to -$405.0 million in 2024, then tumbled by 492.1% to -$2.4 billion in 2025, then sank by 45.75% to -$3.5 billion in 2026.
• Business Quant data shows BMY's Change in Accured Expenses at -$3.5 billion in Q1 2026, -$2.4 billion in Q4 2025, and $1.7 billion in Q3 2025.